ClinicalTrials.gg
RecruitingNCT07597902SHIELDUpdated Oct 28, 2026

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

A Phase 2 interventional study of Valacyclovir and Celecoxib in Post-acute Sequelae of COVID-19 and Long COVID, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai — 6 open to participants now, 7 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Icahn School of Medicine at Mount Sinai.

Planned enrollment
Largest of 10
150 · median 45
Started
2026
with 2 others
Phase 2
2 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 2, and was the 9th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Read the detailed description

This is an off-label, randomized, double-blind, active placebo-controlled, two-arm clinical trial of a combination of celecoxib, valacyclovir, and Paxlovid in adults with Long COVID. This study aims to evaluate the safety and efficacy of the combination of celecoxib, valacyclovir, and Paxlovid in adults with Long COVID (LC). Safety will be primarily measured through blood and urine measures. Efficacy will be evaluated by measuring patient-reported outcomes.

03

Conditions studied

  • Post-acute Sequelae of COVID-19
  • Long COVID
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age at the time of study entry
  • Diagnosed with Long COVID
  • Individuals of must have a negative serum pregnancy test at screening and agree to on-site urine pregnancy testing at all subsequent study visits
  • A urine drug screen performed at the Screening Visit must be negative for drugs of abuse such as methamphetamine, cocaine, phencyclidine (PCP), and non-disclosed amphetamines and opioids/opiates.
  • Those with mild to moderate depression should be clinically stable for three months, without risk of suicidal ideation or behavior.

Exclusion criteria

Exclusion Criteria:

  • Breastfeeding, pregnant, or planning to become pregnant during the next six months.
  • In the opinion of the Investigator, any , uncontrolled, or unstable medical or surgical condition that could affect the individual's ability to participate in the study or potentially compromise their well-being while enrolled in the study.
  • In the opinion of the Investigator or based on results of the HADS, evidence of a clinically significant psychiatric disorder, e.g., severe, unstable or poorly controlled depression, anxiety or obsessive-compulsive disorder; moderate or severe alcohol use disorder; substance use disorder other than mild cannabis use disorder; or any history of bipolar disorder, schizophrenia, schizoaffective disorder or other psychotic disorder.
  • Currently meeting criteria for ME/CFS at the pre-screening or screening visit, or a prior confirmed diagnosis of ME/CFS within the last 5 years. This may be determined as part of the initial screening call or visit.
  • Any anticipated need for surgery that in the opinion of the Principal Investigator or Sub-I might confound results or interfere with the participant's ability to comply with the protocol.
  • Symptomatic and/or otherwise clinically significant cardiac disease
  • Acute non-COVID systemic infection (e.g., , hepatitis) or other active viral or bacterial infection during the screening/ or at the Baseline visit.
  • Currently receiving chronic systemic (>5 mg prednisone daily, or equivalent)
  • Routine treatment with warfarin, heparin, lithium, digoxin, amiodarone, isoniazid, phenytoin, fluconazole, methotrexate, probenecid, or raloxifene. Participants on these medications should not be screened.
  • Uncontrolled sleep apnea.
  • Use of chronic nucleoside analog antiviral suppression therapy within one month of the Screening Visit or requiring on average more than one acute treatment course every two months.
  • Current use of celecoxib either alone or in combination with valacyclovir or famciclovir
  • In the opinion of the Investigator, evidence of current drug or alcohol abuse or dependency, or history of abuse or dependence during the preceding 12 months.
  • The participant has undergone a malabsorptive weight loss procedure (e.g., Roux-en-Y or other bypass procedure).
  • Severe IBS-C or colonic inertia as evidenced by seven or more days between bowel movements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Combination Drug Therapy

    For 14 weeks, receives valacyclovir and celecoxib initially, then addition of Paxlovid for 25 days while decreasing valacyclovir dose, and then returns to valacyclovir at the original dose later.

    Drug: Valacyclovir · Drug: Celecoxib · Drug: Paxlovid

  • Placebo comparator
    Placebo

    For 14 weeks, receives matched placebo capsules and tablets

    Drug: Placebo

Interventions

  • one to two 750mg capsules taken orally in the morning and evening

  • 200mg capsules taken orally in the morning and evening

  • DrugPaxlovid

    one (100mg ritonavir tablet and two 150mg nirmatrelvir tablets) taken orally in the morning and evening

  • DrugPlacebo

    matching placebo capsules and tablets taken orally in the morning and evening

06

What researchers measure

Primary outcomes

  1. EQ-5D-5L Visual Analogue Scale (VAS)

    The EQ VAS records the patient's self-rated health on a visual analogue scale where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0), with higher scores indicating better health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

Secondary outcomes

  1. The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L)

    The EQ-5D-5L is a validated, standardized, generic instrument that is a preference-based health- related quality of life questionnaire. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Full scale from 5 to 25, with higher score indicating poorer health outcomes.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

  2. Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29)

    The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. The values of all item responses are averaged to generate subscores for each dimension. From these subscores, a global physical health score and a global mental health score are generated. The scores are translated into T-scores according to a reference population with a mean of 50 and a standard deviation of 10.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

  3. General Symptom Questionnaire (GSQ-30)

    The General Symptom Questionnaire-30 (GSQ-30) is a valid and reliable instrument to assess symptom burden among patients with acute and post-treatment. The GSQ-30 total score ranges from 0 to 120, with higher scores indicating a greater symptom burden.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

  4. Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a series of questions assessing presence and severity of depression symptoms. It evaluates each of the DSM-IV depression criteria and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Full scale from 0-27, with higher score indicating more severe symptoms.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

  5. Generalized Anxiety Disorder (GAD-7)

    The GAD-7 is a 7-item scale developed and validated to identify generalized anxiety disorder and its severity. It assesses the frequency of 7 anxiety symptoms and scores the responses from 0 ("Not at all") to 3 ("Nearly every day"). Total scores of 5, 10, and 15 correspond to mild, moderate, and severe generalized anxiety disorder, respectively. Full scale from 0-21, with higher score indicating more symptoms.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

  6. COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS)

    A suicide risk assessment tool that supports suicide risk assessment through a series of simple, plain-language questions that anyone can ask. The answers help users identify whether someone is at risk for suicide, assess the severity and immediacy of that risk, and gauge the level of support that the person needs. Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation). Higher score represents poorer health outcomes.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

  7. Neuro-QoL™ v2.0 Cognitive Function-Short Form

    The Neuro-QoL Cognitive Function v2.0 short form assesses perceived difficulties in cognitive abilities, including memory, attention, decision making, planning, organizing, calculating, remembering, and learning. The short form consists of 8 questions assessed on a 5-point Likert scale, resulting in a raw score range of 8 to 40. A raw score is then converted to a T-score using conversion tables. Scores 0.5 - 1.0 SD worse than the mean (T-score 40-45) = mild symptoms/impairment. Scores 1.0 - 2.0 SD worse than the mean (T-score 30-40) = moderate symptoms/impairment. Scores 2.0 SD or more worse than the mean (T-score below 30) = severe symptoms/impairment.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

  8. Single-item Sleep Quality Scale (SQS)

    The SQS is a visual analog scale that instructs respondents to rate their overall quality of sleep over a 7-day recall period from 0 to 10. Scores of 0, 1, 4, 7, and 10 correspond to terrible, poor, fair, good, and excellent, respectively. Higher scores indicate better sleep quality.

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, Week 20

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2028, 20 months after the start.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 20 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 19, 2026
StartActual
Oct 20, 2026was Jun 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) is now Recruiting
Oct 28, 2026
Start date
Jun 1, 2026→Oct 20, 2026 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) is now Recruiting
    Start date Jun 1, 2026→Oct 20, 2026 (now actual)
    + 3 other changes: verification date, responsible party and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07597902
Collaborators
PridCor Therapeutics
Responsible party
David Putrino (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
May 19, 2026
Start date
Oct 20, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

David Putrino, PhD
Contact
CoreResearch@mountsinai.org
212-241-7658
David Putrino, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valacyclovir · Celecoxib

Start the discussion